ArticleCancer research2012
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype.
Article in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 91 citations in OpenAlex.
- Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer.Frontiers in cell and developmental biology · 2026Review
- Overexpression of KRAS enhanced the stemness of esophageal cancer cells inhibited by overexpression of circ0043898.BMC cancer · 2025Article
- Extracellular vesicles and cancer stem cells: a deadly duo in tumor progression.Oncology reviews · 2024Review
- Biomarkers and targeted therapy for cancer stem cells.Trends in pharmacological sciences · 2024Review
- Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?Molecular cancer · 2023Article
- Clinicopathologic Impact of NANOG, ZEB1, and EpCAM Biomarkers on Prognosis of Serous Ovarian Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway.Nature communications · 2023Article
- Review
- Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle.The Journal of clinical investigation · 2022Article
- Article
- LDH-A negatively regulates dMMR in colorectal cancer.Cancer science · 2021Article
- Effect of Nanog overexpression on the metastatic potential of a mouse melanoma cell line B16-BL6.Molecular and cellular biochemistry · 2021Article
- Immune evasion by cancer stem cells.Regenerative therapy · 2021Review
- Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies.Gastroenterology · 2021Review
- Nanog maintains stemness of Lkb1-deficient lung adenocarcinoma and prevents gastric differentiation.EMBO molecular medicine · 2021Article
- Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer.Cancers · 2021Article
- The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?Cellular and molecular life sciences : CMLS · 2021Review
- Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis.Immune network · 2020Review
- HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors.Nature communications · 2020Article
- Immunotherapy: Newer Therapeutic Armamentarium against Cancer Stem Cells.Journal of oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Due to the exquisite specificity and potency of the immune system, vaccination is in theory the most precise and powerful approach for controlling cancer. However, current data from clinical trials indicate that vaccination rarely yields significant benefits for cancer patients in terms of tumor progression and long-term survival. The poor clinical outcomes of vaccination are primarily caused by mechanisms of immune tolerance, especially within the tumor microenvironment. Here, we report that vaccination drives the evolution of tumor cells toward an immune-resistant and stem-like phenotype that promotes tumor growth and nullifies the CTL response. The emergence of this phenotype required the transcription factor Nanog, which is induced as a consequence of immune selection. Nanog expression enhanced the stem-like features of tumor cells and protected them from killing by tumor-reactive CTLs. Delivery of siNanog into tumor-bearing mice rendered the tumor vulnerable to immune surveillance and strongly suppressed its growth. Together, our findings show tumor adaptation to vaccination through gain of an immune-resistant, stem-like phenotype and identify Nanog as a central molecular target in this process. Future vaccination technology should consider Nanog an important target to enhance the immunotherapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.